XBiotech USA Revenue and Competitors
Estimated Revenue & Valuation
- XBiotech USA's estimated annual revenue is currently $19.2M per year.
- XBiotech USA's estimated revenue per employee is $163,761
- XBiotech USA's current valuation is $352.6M. (January 2022)
Employee Data
- XBiotech USA has 117 Employees.
- XBiotech USA grew their employee count by 9% last year.
XBiotech USA's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO & Chairman | Reveal Email/Phone |
2 | VP, Finance and Human Resources and Secretary (Principal Financial Officer) | Reveal Email/Phone |
3 | VP Quality | Reveal Email/Phone |
4 | VP Quality Control | Reveal Email/Phone |
5 | VP Clinical Operations | Reveal Email/Phone |
6 | PharmacoVigilance Officer | Reveal Email/Phone |
7 | Director IT | Reveal Email/Phone |
8 | Associate Director Cell Line Development | Reveal Email/Phone |
9 | Chief Scientific Officer | Reveal Email/Phone |
10 | Senior Director Manufacturing | Reveal Email/Phone |
XBiotech USA Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.7M | 11 | -8% | N/A | N/A |
#2 | $14.9M | 96 | -6% | N/A | N/A |
#3 | $15.2M | 98 | 3% | $1.8M | N/A |
#4 | $1.6M | 10 | 0% | N/A | N/A |
#5 | $3.4M | 22 | 0% | N/A | N/A |
#6 | $2.8M | 18 | 50% | N/A | N/A |
#7 | $7.4M | 48 | -2% | N/A | N/A |
#8 | $0.8M | 5 | 0% | N/A | N/A |
#9 | $1.6M | 10 | 0% | N/A | N/A |
#10 | $16.3M | 105 | 62% | N/A | N/A |
What Is XBiotech USA?
XBiotech is developing a first-in-class monoclonal antibody (MABp1) to inhibit chronic inflammation. Chronic (sterile) inflammatory responses are involved in the progression of many serious and common diseases. MABp1 is being investigated in many important areas of medicine, including: cancer, leukemia (Phase 1); Type 2 diabetes (Phase2); Psoriasis (Phase 2); and vascular disease (Phase 2). MABp1 is a True Human antibody cloned from a natural human immune response andunlike currently marketed antibodiesit has not undergone any modification to alter its function. It has exhibited the best potential tolerability and safety during the clinical trials. XBiotech has established a current good manufacturing practices (cGMP) program to commercialize its lead product candidate. The Company has purchased land and designed a commercial-scale plant with 25,000L total bioreactor capacity. Construction of the facility is planned to commence in 4th quarter 2011..
keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power
N/A
Total Funding
117
Number of Employees
$19.2M
Revenue (est)
9%
Employee Growth %
$352.6M
Valuation
N/A
Accelerator
XBiotech USA News
... Size 2022-2030| Key Players Abbvie Inc, Handok Inc, Xbiotech Inc, ... New Jersey, USA,- The research study presented here is a very detailed and...
Share Share on Facebook Share on Twitter LinkedIn Email Reprints Xbiotech, an Austin, TX-based company founded a decade ago, has taken its mission to develop drugs from naturally occurring monoclonal antibodies to the public markets. The company sold 4 million shares at $19 a piece, in the midd ...
Other Companies in Austin
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $21.1M | 117 | 24% | N/A |
#2 | $28.7M | 117 | -7% | N/A |
#3 | $38.4M | 117 | 4% | N/A |
#4 | $18.7M | 117 | 17% | N/A |
#5 | N/A | 117 | 24% | N/A |